Cogent Biosciences (COGT) EBITDA (2017 - 2026)

Cogent Biosciences (COGT) has reported EBITDA for 10 consecutive years, with -$103.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA fell 38.27% year-over-year to -$103.6 million; the TTM figure through Mar 2026 stood at -$362.0 million (down 25.5% YoY), while the FY2025 annual figure was -$333.4 million, down 20.81% from the prior year.
• EBITDA declined to -$103.6 million in Q1 2026 per COGT's latest filing, from -$99.5 million in the prior quarter.
• Across five years, EBITDA topped out at -$31.4 million in Q1 2022 and bottomed at -$103.6 million in Q1 2026.
• Historically, EBITDA has averaged -$62.9 million across 5 years, with a median of -$62.4 million in 2024.
• Annual changes were most pronounced in 2022 — EBITDA tumbled 145.45% — and 2025, when it slipped 10.53%.
• Cogent Biosciences' EBITDA stood at -$43.7 million in 2022, then tumbled by 33.11% to -$58.2 million in 2023, then decreased by 26.63% to -$73.7 million in 2024, then sank by 34.94% to -$99.5 million in 2025, then dropped by 4.13% to -$103.6 million in 2026.
• Business Quant data shows COGT's EBITDA at -$103.6 million in Q1 2026, -$99.5 million in Q4 2025, and -$83.4 million in Q3 2025.